Restylane: Products, Cost, Results and Where to Get It

Restylane is Galderma's family of hyaluronic acid (HA) dermal fillers — injectable gels that FDA regulates as medical device implants, approved to create a smoother or fuller appearance in the face, including the nasolabial folds (smile lines), cheeks, chin, lips and the back of the hands.

Hyaluronic acid is a sugar (polysaccharide) naturally present in skin and cartilage, per FDA; the HA in fillers is made from bacteria or rooster combs and is often chemically crosslinked so it holds up longer.

Restylane's gels — Kysse, Lyft and Eyelight, for example — are described in their labeling as hyaluronic acid generated by bacteria and crosslinked with BDDE, at 20 mg/mL with 0.3% lidocaine.

The original Restylane is the founding product: FDA approved it on March 25, 2005 — Galderma's NASHA gel, under premarket approval (PMA) P040024 — for correction of moderate to severe facial wrinkles and folds such as nasolabial folds.

In 2011 Restylane became the first US filler with a lip indication in FDA's approval record, and lidocaine-containing Restylane-L followed with the same lip indication in 2012. The line grew from there; the products in this guide trace to two PMAs — P040024 (Restylane, Restylane-L, Silk, Lyft, Eyelight) and P140029 (Refyne, Defyne, Kysse, Contour).

Because approvals are product-specific, "Restylane" is not one thing: the same brand can be on-label in one area and off-label in another, and one product's approval never transfers to another.

Every Restylane approval covered in this guide names patients over 21; FDA's general statement for fillers is adults aged 22 or older, with each product's label setting the exact age.

Restylane is one of several filler families sold in the US.

The dermal fillers guide covers the other brands and materials, from other hyaluronic acid lines to calcium hydroxylapatite and poly-L-lactic acid.

Each Restylane product carries its own approved indications, with the year each use was approved.

The record below comes from FDA's PMA approvals.

Every approval above names patients over 21.

Galderma's own site maps the line the same way: Kysse and Silk for lips, Lyft and Contour for cheeks, Defyne for the chin, Defyne, Lyft, Refyne and Restylane for smile lines, Lyft for the backs of the hands, Eyelight for under-eye hollows, and Contour "Approved for Temple Hollowing." The brand page is marketing, though: when it was read for this guide in October 2026, it still routed chin questions to Defyne alone, although FDA had approved Lyft for the chin in November 2025 — one more reason to treat the PMA record, not the brochure, as the list to check.

Under the eyes, Restylane Eyelight is one of only four US fillers with an approved infraorbital-hollow indication as of October 2026 — the others are Juvéderm Volbella XC, Belotero Balance (+) and RHA Redensity Eye — so any other Restylane product, Restylane-L for example, is off-label under the eyes.

Outside a product's own approval, a use is off-label: it is not on any current US label for that product.

The approval record shows how easy it is to cross that line.

As of October 2026, no US dermal filler holds an indication for the nose, so a "non-surgical nose job" is off-label with any filler, Restylane included.

FDA's general filler page lists the glabella, nose, periorbital area, forehead and neck among uses the agency has not approved — though product-specific approvals for under-eye hollows and neck lines have arrived since that page was written, which is exactly why on-label status gets checked product by product.

And as of October 2026, the two US jawline indications on file belong to Juvéderm Volux XC and Radiesse (+), not to any Restylane product.

The amount of gel is measured in milliliters, and labels cap how much can be injected per treatment — the Restylane Lyft label, for example, sets per-treatment maximums of 6.0 mL for wrinkles and folds, 6.0 mL for the cheeks or midface, 3.0 mL per hand, and 4 mL for the chin (including touch-up, no more than 2 mL per injection site).

Those are safety ceilings, not recommended or typical amounts — not a prediction of what any one treatment will take.

The closest national figure is ASPS's average cost of $715 for hyaluronic acid fillers ($743 for lip augmentation with filler).

Those are average fees reported by ASPS member plastic surgeons — not med spa prices — and the ASPS page does not state the data year.

Restylane products are hyaluronic acid fillers, so that average is a reference point, not a price you can book.

What moves the price: ASPS names the injector's expertise and qualifications, the type of procedure, the time and effort required and the geographic location of the office — and notes that health insurance does not cover dermal fillers.

We could not find a published per-syringe price for any specific Restylane product in the manufacturer and professional-society sources we checked on October 20, 2026 — the Restylane products in that check were Eyelight, Lyft and Contour.

Your real number is local, so ask any provider you are considering for a written quote that names the exact product, the amount in mL, and the total including any touch-up.

For a fuller cost breakdown, see how much Restylane costs.

Galderma's rewards program can discount the sticker price.

The ASPIRE Galderma Rewards program earns points on qualifying Galderma treatments, including Restylane.

Per Galderma's Restylane site, ASPIRE offers a $20-off welcome reward, 100 points = $10 in savings, and up to 600 points per visit; the program's published terms also list Restylane at 200 points per syringe, with a 1,000-point treatment maximum per visit and a 2,000-point annual treatment earning limit.

Terms change, so check them before you book.

FDA's general duration estimate for hyaluronic acid fillers — the material every Restylane product is made of — is approximately 6 to 12 months, and FDA groups HA among the absorbable (temporary) filler materials.

Beyond that material-level estimate, the figures below are responder rates from the pivotal trials of the products that have them: the share of subjects a blinded evaluator still rated improved by at least one point or grade at each study visit.

Read the curves, not the endpoints.

The rates in these series mostly drift lower over follow-up — the temple series rises to 94.6% at month 6 and holds at 91.6% at month 12 before falling to 86.1% at month 18 — each row measures something different (lip fullness, hollowing, chin contour, cheek volume, temple hollowing), and the rates are therefore not comparable across rows.

The cheek figure comes from Galderma's own head-to-head trial against Juvéderm Voluma XC, in which the two products tracked similarly and traded places over time — a trial designed to test similarity, not to crown a winner.

One more finding is worth knowing: the visible result and the physical gel are not the same thing.

In an MRI study of 33 patients, mid-face HA filler was still detectable in all of them at least 2 years after injection, with some filler visible 8 to 15 years later — evidence that hyaluronic acid can persist in tissue after the visible effect fades.

The study was small and covered the mid-face only.

FDA's filler-wide risk list runs in tiers.

Common risks: bruising, redness, swelling, pain, tenderness, itching and rash.

Less common: nodules or granulomas, infection, allergic reaction and necrosis.

Rare reported risks: anaphylaxis, migration of filler, permanent hard nodules, blindness, stroke and death.

On timing, FDA says side effects such as swelling and bruising generally appear soon after injection and many resolve in days to weeks, while some can appear weeks, months or years later.

The most granular numbers published for a Restylane product that we found come from the Restylane Eyelight under-eye trial.

After the initial injection, subjects' diaries most often reported tenderness (89.7%), swelling (85.0%), bruising (63.1%), redness (61.5%), pain (59.8%) and lumps or bumps (53.5%); swelling lasted 2 to 7 days in 76.6% of subjects and 14 to 28 days in 2.0%.

The median time until subjects felt comfortable returning to social engagement was within 4 hours after needle treatment and within 12 hours after cannula treatment.

These are trial figures for one product in one area, not guarantees for any treatment.

Who should be cautious: FDA says filler safety is unknown during pregnancy and breastfeeding, in people under 22 and in people prone to keloid or hypertrophic scarring, and that treatment should be delayed if the skin in the area is inflamed or infected.

FDA also says to tell the provider about bleeding disorders, severe allergies or anaphylaxis, and allergies to lidocaine, collagen, eggs, animal products or bacteria — relevant here because Restylane gels such as Kysse, Lyft and Eyelight contain 0.3% lidocaine.

And if you are considering filler alongside a toxin such as Botox, FDA notes that the safety of fillers combined with neuromodulators has not been evaluated in controlled clinical studies.

Restylane and Juvéderm sit in the same category: crosslinked hyaluronic acid gels with lidocaine, sold product by product, each with its own FDA approvals.

The differences start with the makers — Galderma for Restylane, Allergan for Juvéderm — and continue in the gel engineering each describes.

Allergan says several Juvéderm products use its proprietary VYCROSS technology, which blends different molecular weights of hyaluronic acid, while Restylane gels such as Kysse, Lyft and Eyelight are bacterial-origin HA crosslinked with BDDE at 20 mg/mL with 0.3% lidocaine.

Technology names are marketing descriptions, not proof that one gel performs better.

One trial in the labels we read pits a Restylane product directly against a Juvéderm product: Galderma's cheek study randomized Restylane Contour against Juvéderm Voluma XC at a 2:1 ratio with a needle.

Blinded-evaluator responder rates were 91.2% versus 87.7% at week 12, 88.5% versus 83.1% at week 24, 72.1% versus 83.6% at week 36 and 62.8% versus 65.1% at week 48 — similar results that traded places over time, in a trial designed to test similarity rather than superiority.

Lips are the clearest comparison, and even there the measures differ.

Both families carry FDA-approved lip fillers; among them are Allergan's Volbella XC (2016) and Restylane Kysse (2020).

Allergan says Volbella lip results hold up to 1 year with optimal treatment, a manufacturer claim, while Kysse's pivotal trial measured 60% of subjects still responders at week 48.

No head-to-head trial between them appears in the labels we read, so neither can fairly be called longer-lasting.

The Juvéderm guide covers Allergan's collection product by product, and the lip filler guide compares the FDA-approved lip options.

The approval maps also diverge area by area.

Restylane Lyft holds a back-of-the-hands indication that no Juvéderm product shares — only two US fillers are approved there, Lyft and Radiesse.

Juvéderm holds the jawline indication (Volux XC) that no Restylane product shares.

Under the eyes, Juvéderm Volbella XC was approved first (2021), with Restylane Eyelight following in 2023.

Which product fits which area — and which of the two families a provider keeps in stock — is a question for a licensed provider who can examine your face.

FDA's advice is concrete: choose a licensed health care provider with dermatology or plastic-surgery experience who is trained in filler injection, and treat the appointment as what FDA says it is — a medical procedure, not a cosmetic treatment.

Who may hold the syringe is decided state by state.

AmSpa, the American Med Spa Association, describes a common delegation model: nurse practitioners inject with documented training under a collaborative agreement or full practice authority; registered nurses — or, where a state allows it, LPNs/LVNs or medical assistants — inject only with documented training, after a patient exam and treatment order from a physician (or a delegated PA/NP), with the physician on site or promptly reachable; and unlicensed people cannot inject on their own.

That is a trade association's general description, not every state's law, so check your state's medical or nursing board rules before you book.

Emergency readiness is a question any consultation should answer easily: FDA tells injectors to know the signs of an intravascular injection, to keep an updated plan for treating one — on site or by immediate referral — and to stop injecting at warning signs such as skin blanching, vision change, stroke signs or unusual pain.

Buy the real thing, from a provider: FDA says no filler is approved for over-the-counter sale, advises people not to inject themselves or buy filler online, and warns that needle-free injection devices are not approved for dermal fillers.

For the full vetting checklist — credentials, red flags, memberships and payment options — the med spa choice guide works through it step by step.